Alle Aktivitäten

J Dermatol. 2025 Feb 3. doi: 10.1111/1346-8138.17645. Online ahead of print. ABSTRACT The association between psoriasis and streptococcal infection has been widely explored in both children and adults. However, the exact impact of Streptococcus pharyngeal infection on the course of psoriasis is not fully comprehended. This study explored the impact of Streptococcus pharyngeal infection on psoriasis and investigated the effectiveness of systemic antibiotic therapy in conjunction with standard topical treatment for psoriatic patients with concomitant streptococcal throat infection. The research involved 115 patients with mild-to-moderate psoriasis, clinically assessed using the Psoriasis Area and Severity Index (PASI). Patients with active streptococcal infection were administered adjunctive systemic antibiotic therapy along with standard local treatment for psoriasis, while psoriasis patients without evidence of infection received the local topical treatment only. Streptococcal infections were more common in psoriasis patients compared to healthy controls. A group of psoriasis patients with active streptococcal throat infections, treated with antibiotics in addition to standard topical psoriasis therapy, did not show any difference in PASI score reduction compared to those without evidence of active infection. While our study did not show a statistically significant reduction in PASI scores in psoriasis patients with streptococcal throat infections treated with antibiotics, it highlights the complex interaction between infection and psoriasis. Larger studies with longer follow-up may better clarify this relationship, contributing to stronger evidence for or against the use of antibiotics in managing psoriasis triggered by streptococcal infections. PMID:39895559 | DOI:10.1111/1346-8138.17645 Den ganzen Artikel lesen

Indian J Dermatol. 2025 Jan-Feb;70(1):42-46. doi: 10.4103/ijd.ijd_719_24. Epub 2024 Dec 30. ABSTRACT Behçet's disease is a chronic inflammatory condition that affects multiple organs and systems. It is characterized by recurrent oral and genital ulcers. A previous study reported that the IL-17A inhibitor secukinumab can improve the skin and mucosal manifestations in patients with refractory Behçet's disease. Additionally, secukinumab has been shown to effectively improve neurological symptoms when administered for Behçet's disease. However, we report a case where Behçet's disease occurred after the treatment of psoriasis with the IL-17A inhibitor ixekizumab. To summarize its clinical characteristics and treatment experience, we consulted relevant domestic and international literature and conducted a literature review. We concluded that anti-IL-17A treatment may lead to the development of Behçet's disease. The reported cases are more likely to occur in middle-aged men with varying onset times. The main manifestations include oral and vulvar mucosal ulcers. Furthermore, the gut microbiota may be involved in paradoxical Behçet's disease. PMID:39896301 | PMC:PMC11784972 | DOI:10.4103/ijd.ijd_719_24 Den ganzen Artikel lesen

Cureus. 2025 Jan 3;17(1):e76869. doi: 10.7759/cureus.76869. eCollection 2025 Jan. ABSTRACT While topical steroids are an invaluable tool used for the treatment of pruritic rashes, they can also complicate attempts at a definitive diagnosis. The temporal association between steroid use and biopsy must be taken into account when investigating the underlying etiology of such rashes. In patients with a history of dermatologic disease with the onset of a new rash, management should include a biopsy, if deemed necessary for diagnosis, followed by a prescription of topical steroids for symptomatic treatment. A 63-year-old male with a history of psoriasis presented with a new-onset pruritic, erythematous-to-violaceous rash on sun-exposed areas. The final diagnosis of subacute cutaneous lupus erythematosus (SCLE) was delayed due to the use of topical steroids on cutaneous eruptions before presentation in the clinic for biopsy. Diagnosis of SCLE can be difficult, especially for primary care providers who do not see the initial presentation regularly, as cutaneous findings can be variable in presentation. However, recurrent eruptions in similar photo-distributed locations should alert providers of a potential underlying diagnosis and prompt referral for dermatologic evaluation should be suggested. Thorough personal and family history should be taken and photographs of the rash should be documented in the patient's chart for future reference. Ultimately, biopsy is the gold standard diagnostic method for evaluating the etiology of new-onset rash. When there is suspicion of an underlying disease beyond idiopathic contact or irritant dermatitis, a biopsy should be considered as the next best step in management. PMID:39897333 | PMC:PMC11787870 | DOI:10.7759/cureus.76869 Den ganzen Artikel lesen

Ther Adv Musculoskelet Dis. 2025 Jan 31;17:1759720X251315138. doi: 10.1177/1759720X251315138. eCollection 2025. ABSTRACT BACKGROUND: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in everyday clinical practice. OBJECTIVES: To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinical response and treatment discontinuation in patients with moderate-to-severe PsA, using real-world data from the Italian Group for the Study of Early Arthritis (GISEA) registry. DESIGN: This longitudinal retrospective study included PsA patients treated with SECU, spanning from May 2016 to November 2023. METHODS: Data from 1045 PsA patients, including 783 with peripheral-only PsA (perPsA) and 262 with peripheral and axial involvement (mixed PsA) were analyzed. Drug survival was estimated by Kaplan-Meier analysis. Clinical outcomes, including Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriasis Area Severity Index (PASI), Ankylosing Spondylitis Disease Activity Score (ASDAS, C-Reactive Protein (CRP)-based), and Visual Analogue Scale (VAS) measures, were evaluated at baseline and at 6, 12, and 24 months. Adjusted hazard ratios (aHRs) for discontinuing SECU were determined using multivariate Cox regression models. RESULTS: SECU survival at 24 months was 63.24%, significantly higher in mixed PsA compared to perPsA (p = 0.036). In the overall PsA population, DAPSA scores decreased significantly at 6 months, and further at 24 months (all p < 0.0001). In mixed PsA, ASDAS-CRP scores were significantly reduced at 6 months and remained stable through 24 months (all p < 0.0001). VAS pain scores also improved already at 6 months and continued to improve at 24 months (all p < 0.0001). Higher age (aHR = 0.98, 95% confidence interval (CI): 0.96-0.99, p = 0.007) and lower baseline DAPSA scores (aHR = 1.02, 95% CI: 1.01-1.03, p = 0.014) were associated with greater persistence of SECU treatment. SECU was well tolerated, with no serious adverse events. CONCLUSION: SECU showed sustained clinical improvements in both peripheral and axial involvement of PsA patients over 24 months, with higher persistence observed in mixed PsA patients. Our findings highlight the favorable clinical and safety profile of SECU in real world. PMID:39897378 | PMC:PMC11783553 | DOI:10.1177/1759720X251315138 Den ganzen Artikel lesen

SAGE Open Med Case Rep. 2025 Jan 31;13:2050313X251317763. doi: 10.1177/2050313X251317763. eCollection 2025. ABSTRACT Palmoplantar plaque psoriasis is more resistant to therapy compared to other phenotypes of psoriasis. To our knowledge, there are no reports of the efficacy of Janus kinase (JAK) inhibitors for palmoplantar plaque psoriasis. Two adult females presented with more than 6-year histories of severe palmoplantar plaque psoriasis. The first patient had failed topical therapies, phototherapy, acitretin, and secukinumab. The second patient had failed topical therapies and systemic agents including alitretinoin, cyclosporine, apremilast, ustekinumab, ixekizumab, and risankizumab. Both cases were switched to upadacitinib 15 mg daily, with a complete response by 3 months of therapy and no adverse events. The first patient had slightly elevated fasting triglyceride and the second patient had elevated ALT, both of which are being monitored. This case series highlights the efficacy of upadacitinib in two patients with refractory palmoplantar plaque psoriasis. JAK1 inhibitors may be considered as third-line therapeutic options in patients with refractory palmoplantar plaque psoriasis and no contraindications to JAK inhibitors. PMID:39897569 | PMC:PMC11786266 | DOI:10.1177/2050313X251317763 Den ganzen Artikel lesen

JAAD Int. 2024 Nov 14;19:12-20. doi: 10.1016/j.jdin.2024.09.015. eCollection 2025 Apr. ABSTRACT BACKGROUND: There is limited evidence on treating psoriasis patients with skin of color (SOC), contributing to disparities in accessing appropriate care for these patients. OBJECTIVES: This study aimed to develop consensus statements defining SOC terminology and addressing needs to optimize the clinical management of psoriasis in patients with SOC. METHODS: Using the modified Delphi methodology 16 Canadian dermatologists with expertise in psoriasis developed consensus statements. Four core faculty members drove the content of the study, and 12 additional panel members were consulted to vote and provide consensus on the content produced by the core faculty. At a final meeting, the full panel revised and voted on the final consensus statements. RESULTS: The exercise resulted in 11 consensus statements on SOC terminology, as well as 5 primary and 4 secondary statements on clinical presentation and differential diagnosis, and treatment guidelines based on evidence and expert opinion. Four additional consensus statements on current assessment tools and access to care were developed based solely on expert opinion. LIMITATIONS: The available evidence was limited, low quality, and inappropriate for formal quality assessment. CONCLUSIONS: The consensus statements developed in this study may provide valuable guidance to the dermatology community treating psoriasis patients with SOC. PMID:39898016 | PMC:PMC11783118 | DOI:10.1016/j.jdin.2024.09.015 Den ganzen Artikel lesen

Int J Med Sci. 2025 Jan 1;22(3):558-564. doi: 10.7150/ijms.102434. eCollection 2025. ABSTRACT Background: Recent studies suggest a potential link between HS and renal dysfunction. Our objective is to assess the correlation between hidradenitis suppurativa (HS) and renal consequences, specifically focusing on acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). Methods: This study was performed based on retrospective cohort design. Electronic medical records of participants were retrieved from the US collaborative network in the TriNetX research network. Information from 46,561 individuals with HS was examined alongside an equivalent number of matched controls. Propensity matching was performed for matching confounders. The study spanned from January 1, 2005, to December 31, 2017. Primary outcomes were set as renal dysfunction, including AKI, CKD, and ESRD. Results: Over the 1-year follow-up, people with HS presented a 1.84-fold higher risk of AKI (95% CI, 1.34-2.53) and a 1.37-fold higher risk of CKD (95% CI, 1.02-1.85) than non-HS individuals. Elevated risks persisted over the longer follow-up periods for AKI at 1.51-fold (95% CI, 1.28-1.77) for 3-years-follow-up and 1.47-fold (95% CI, 1.30-1.65) for 5-years-follow-up, respectively. Stratification by sex revealed higher risks in males, and comparison with psoriasis patients indicated increased AKI and CKD risks in HS patients. Conclusion: This study highlights a significant association between HS and renal dysfunction, emphasizing the need for further exploration of shared pathophysiological mechanisms. The findings could offer potential insights into HS-related comorbidities. PMID:39898256 | PMC:PMC11783075 | DOI:10.7150/ijms.102434 Den ganzen Artikel lesen

Ital J Dermatol Venerol. 2024 Dec;159(6):599-606. doi: 10.23736/S2784-8671.24.07914-3. ABSTRACT BACKGROUND: Biologic drugs have revolutionized the treatment of psoriasis and other chronic inflammatory diseases. In recent years, numerous biosimilar molecules that target cytokines such as TNF-alpha or its receptors have been developed. The approval of biosimilars has made it possible to reduce the costs of biologic drugs, thereby increasing access to these therapies for more patients and enhancing psoriasis treatment globally. Imraldi and Idacio are both biosimilars of Adalimumab, approved for treating moderate to severe psoriasis. METHODS: Our study aims to compare these two adalimumab biosimilars in psoriasis patients who have previously undergone treatment with other biologic drugs or systemic therapy in a real-life setting. Our cohort comprised 32 psoriatic patients. Of these patients, 15 were prescribed Imraldi, while the remaining were on Idacio. To assess the efficacy of these therapies, we utilized various measures including the Psoriasis Area and Severity Index, the Pruritus Visual Analog Scale, the Visual Analog Scale, the Dermatology Life Quality Index, and the Psoriasis Global Assessment, monitoring the patients over a 24-week period. RESULTS: Our results indicated that the use of Idacio led to greater decreases in all scores compared to Imraldi. However, in terms of safety and efficacy, the two drugs were found to be comparable. CONCLUSIONS: The findings of this study support the efficacy and safety of Idacio and Imraldi in managing psoriasis, with Idacio demonstrating superior efficacy in reducing disease severity. Future studies could benefit from expanding the patient cohort and conducting further analyses to evaluate individual responses to treatment. PMID:39898378 | DOI:10.23736/S2784-8671.24.07914-3 Den ganzen Artikel lesen

Ital J Dermatol Venerol. 2024 Dec;159(6):663-675. doi: 10.23736/S2784-8671.24.08083-6. ABSTRACT The introduction of systemic biologic therapies marked a significant advancement in the treatment of moderate to severe psoriasis. However, the high cost associated with these treatments has considerably restricted their widespread utilization. The expiration of biologic patents has allowed the development of biosimilars - medications that are highly similar to approved biologics. Biosimilars hold the promise of reducing treatment costs, thereby enhancing patient access to biologic therapies and contributing to the sustainability of healthcare spending. Nonetheless, the unique regulatory pathways for biosimilars introduce uncertainties regarding their application in real-world psoriasis care. Adoption and regulation of biosimilars differ considerably across countries, reflecting diverse approaches and priorities within global healthcare systems. Potential variations between biosimilars and their originator biologics raise questions about their comparative effectiveness and safety. Current evidence supporting biosimilars for psoriasis treatment is largely based on a limited number of randomized controlled trials (RCTs), with a notable lack of robust real-world evidence. As more biosimilars enter the market, evaluating their use in real-world settings is crucial to identify any differences in effectiveness and safety compared to originators or to enhance their uptake by improving the perceptions of physicians and patients. This review explores the opportunities and challenges presented by biosimilars and underscores the existing gaps in evidence regarding their use in psoriasis treatment. PMID:39898381 | DOI:10.23736/S2784-8671.24.08083-6 Den ganzen Artikel lesen

Ital J Dermatol Venerol. 2024 Dec;159(6):684-685. doi: 10.23736/S2784-8671.24.08051-4. NO ABSTRACT PMID:39898382 | DOI:10.23736/S2784-8671.24.08051-4 Den ganzen Artikel lesen

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and …Den ganzen Artikel lesen

FEBS Open Bio. 2025 Jan 17. doi: 10.1002/2211-5463.13969. Online ahead of print. ABSTRACT Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis. Isosorbide di-(methyl fumarate) (IDMF), a novel derivative of DMF, was synthesized to circumvent this adverse reaction and unlock the potential of topical delivery, which could be useful for treating psoriasis in the subpopulation of psoriatic MS patients, as well as in the general population. Here, we compared its therapeutic potential of this non-sensitizing derivative with DMF and its therapeutic version Diroximel in three skin- and neuroinflammation models: the lck-GFP zebrafish, activated BV-2 murine microglia and human T-lymphocyte Jurkat cell line. The results provide a comparative evaluation of the bioactivity of these three related chemical entities in models relevant to skin and neuroinflammation and expose several therapeutic advantages unique to IDMF. PMID:39825608 | DOI:10.1002/2211-5463.13969 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):286. doi: 10.1007/s00403-025-03818-7. ABSTRACT Atherosclerosis, in which chronic inflammation is also effective in it's pathogenesis, is an important cause of morbidity and mortality in psoriasis patients. Early diagnosis and management of atherosclerosis is important. Measurement of carotid intima media thickness is a method used to determine subclinical atherosclerosis. Our aim in this study is to evaluate subclinical atherosclerosis in psoriasis patients and to examine the effects of targeted therapies on atherosclerosis. This study included 105 psoriasis patients who applied to psoriasis outpatient clinic between May 2022 and December 2022. The patients' age, gender, psoriasis area severity index (PASI) and the initiated treatment agent (topical treatment, sekukinumab, iksekizumab, guselkumab, risankizumab) were noted. Carotid intima-media thickness measurements were taken at baseline and after 6 months of treatment. In patients who were treated with secukinumab, ixekizumab, risankizumab, and guselkumab, there was a statistically significant decrease in catorid-intima media thickness at 6th month when compared with the baseline measurements (p = 0,002 p < 0,001 p < 0,001 p = 0,036 p < 0,001). On the other hand, an increase in the thickness was observed in the topical treatment group. According to our study results, targeted systemic treatments contribute to the improvement of subclinical atherosclerosis in psoriasis patients, while this effect was not seen in topical treatments. These results are consistent with literature data reporting that psoriasis is a systemic inflammatory disease. PMID:39825924 | DOI:10.1007/s00403-025-03818-7 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):282. doi: 10.1007/s00403-024-03676-9. ABSTRACT One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis. This randomized prospective intra-patient comparative study was carried out on 30 patients with scalp psoriasis. Lesions were divided randomly into two areas: Area A and Area B. Area A received biweekly sessions of 308-nm excimer light and Area B received topical MTX 1% hydrogel once daily for 3 consecutive months. Psoriatic Scalp Severity Index (PSSI), itching score, patient satisfaction and dermoscopic red dots and white scales were used for assessment at the baseline, at the end of treatment protocol and 1 month after the last treatment session. Both treatment modalities induced significant improvement in PSSI, itching score and dermoscopic red dots and white scales (p < 0.001 for each). The mean percentage of improvement of PSSI was 75.82 ± 33.72 in Area A and 74.19 ± 31.64 in Area B with non-significant difference between both areas (p = 0.763). Moreover, the mean percentage reduction of itching score was 77.40 ± 24.61 in Area A and 67.67 ± 34.94 in Area B with non-significant difference between both areas (p = 0.430). Additionally, a notable improvement in dermoscopic red dots and white scales was observed in 83.3% of patients in Area A and in 60% in Area B at the end of treatment protocol with non-significant difference between both areas (p = 0.518) (p = 0.436). Marked patient satisfaction was noticed in both areas with non-significant difference between both areas (p = 0.433). 308-nm excimer light and topical MTX 1% hydrogel are equally safe and effective treatment options for scalp psoriasis with minimal side effects. PMID:39825943 | DOI:10.1007/s00403-024-03676-9 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):291. doi: 10.1007/s00403-024-03786-4. ABSTRACT This study aims to explore the measurement agreement between direct and indirect health utility measures in four chronic dermatological conditions (atopic dermatitis, hidradenitis suppurativa, pemphigus, psoriasis). Outpatients survey data collected between 2015 and 2021 were analysed. Health-related quality of life (HRQoL) outcome measures included time trade-off (TTO), EQ-5D-5L and Dermatology Life Quality Index (DLQI). Descriptive statistics were computed for the pooled sample and four diseases. Mean, standard deviation (SD), median, interquartile range (IQR), ceiling and floor effects were calculated for TTO, EQ-5D-5L and DLQI utilities. Bland‒Altman plots and intraclass correlation coefficients (ICC) were applied to investigate the agreement between health utility measures. Sociodemographic characteristics (age, sex, educational level, employment status) and health-related information (disease duration, outpatient care visits in the past 3 months and disease severity) impact on utilities was investigated by Tobit regressions. The sample includes N = 765 patient responses with a mean age of 41.5 (SD = 16.2), majority being males (52.7%). Total sample mean utilities were the highest according to TTO (0.83), followed by EQ-5D-5L and vDLQI (0.81 and 0.81) and lowest in mDLQI (0.77). Measurement agreement was found only between TTO and EQ-5D-5L. Skin-disease severity impacted all health state utilities, though only TTO differentiated utility values according to disease type. The discrepancies between the TTO and DLQI warn to compare DLQI-based utilities in different dermatological conditions with extreme caution. PMID:39825944 | DOI:10.1007/s00403-024-03786-4 Den ganzen Artikel lesen

Sci Rep. 2025 Jan 17;15(1):2346. doi: 10.1038/s41598-025-86976-y. ABSTRACT Brodalumab, a humanized monoclonal antibody that targets the interleukin-17 receptor A, is primarily used to manage moderate-to-severe plaque psoriasis. Although it has demonstrated favorable efficacy and safety in clinical trials, the strict inclusion and exclusion criteria may not fully reflect its safety profile in real-world settings. As its use becomes more widespread in clinical practice, understanding its safety in real-world applications is crucial.This study employed disproportionality analysis to assess the safety of brodalumab by examining all adverse event reports that identified brodalumab as the primary suspected drug in the FDA Adverse Event Reporting System database since 2017. Techniques such as the Reporting Odds Ratio, Proportional Reporting Ratio, Multi-item Gamma Poisson Shrinker, and Bayesian Confidence Propagation Neural Network were utilized to analyze the adverse events associated with brodalumab. Additionally, the Weibull distribution was used to model the temporal risk of adverse events.The study identified several adverse reactions already listed on the drug's label that showed positive signals, including arthralgia, headache, myalgia, suicidal ideation, oropharyngeal pain, injection site mass, and infections. Additionally, we found potential adverse reactions not noted on the drug's label that exhibited positive signals, including depression, increased blood pressure, peripheral swelling, gait disturbance, inability to walk, stress, myocardial infarction, sepsis, uveitis, nephrolithiasis, and interstitial lung disease. Moreover, this analysis highlighted the critical need for vigilant monitoring of adverse events, especially during the first month following the initiation of treatment.This study provides initial insights into the real-world safety of brodalumab, confirming known adverse reactions and uncovering additional potential risks. The results deliver vital information that can assist clinicians in making informed decisions when prescribing brodalumab for psoriasis treatment. PMID:39824966 | DOI:10.1038/s41598-025-86976-y Den ganzen Artikel lesen

Cell Mol Biol Lett. 2025 Jan 17;30(1):7. doi: 10.1186/s11658-025-00685-y. ABSTRACT The skin is a barrier that protects the human body against environmental factors (physical, including solar radiation, chemicals, and pathogens). The integrity and, consequently, the effective metabolic activity of skin cells is ensured by the cell membrane, the important structural and metabolic elements of which are phospholipids. Phospholipids are subject to continuous transformation, including enzymatic hydrolysis (with the participation of phospholipases A, C, and D) to free polyunsaturated fatty acids (PUFAs), which under the influence of cyclooxygenases (COX1/2), lipoxygenases (LOXs), and cytochrome P450 (CYPs P450) are metabolized to various classes of oxylipins, depending on the type of PUFA being metabolized and the enzyme acting. The most frequently analyzed oxylipins, especially in skin cells, are eicosanoids, which are derivatives of arachidonic acid (AA). Their level depends on both environmental factors and endogenous metabolic disorders. However, they play an important role in homeostasis mechanisms related to the structural and functional integrity of the skin, including maintaining redox balance, as well as regulating inflammatory processes arising in response to endogenous and exogenous factors reaching skin cells. Therefore, it is believed that dysregulation of eicosanoid levels may contribute to the development of skin diseases, such as psoriasis or atopic dermatitis, which in turn suggests that targeted control of the generation of specific eicosanoids may have diagnostic significance and beneficial therapeutic effects. This review is the first systemic and very detailed approach presenting both the causes and consequences of changes in phospholipid metabolism leading to the generation of eicosanoids, changes in the level of which result in specific metabolic disorders in skin cells leading to the development of various diseases. At the same time, existing literature data indicate that further detailed research is necessary to understand a clear relationship between changes in the level of specific eicosanoids and the pathomechanisms of specific skin diseases, as well as to develop an effective diagnostic and therapeutic approach. PMID:39825220 | DOI:10.1186/s11658-025-00685-y Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):256. doi: 10.1007/s00403-025-03810-1. NO ABSTRACT PMID:39820719 | DOI:10.1007/s00403-025-03810-1 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 17;317(1):269. doi: 10.1007/s00403-025-03808-9. ABSTRACT Psoriasis is associated with psychological distress among the affected due to unsightly skin lesions, chronicity and the cultural and social stigma linked with the disease. The pathophysiological link between psoriasis and depression creates a vicious cycle in the skin and brain axis. This study evaluates the psychological comorbidity of patients with chronic plaque psoriasis (CPP). A cross-sectional study was conducted among 297 patients aged 18 years or more attending dermatology clinics at National Hospital, Galle and General Hospitals at Matara and Hambantota. The Sinhala validated Kessler Psychological Distress Scale (K10), and patient health questionnaire (PHQ-9) were used to assess psychological status and depression, respectively. The quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI). Mean (SD) age of patients was 52(12) years and 57.6% were males. According to the K10 score, 73% (n = 218) were likely to be mentally robust while 15% (n = 45) had mild mental disorder and 11% (n = 34) had moderate to severe mental disorder. Screening using PHQ-9 showed 17%(n = 51) prevalence of depression and 14% (n = 42) reported to have had suicidal ideation at some stage of the illness. Psychological distress showed weak correlations with age (ρ= -0.19, p < 0.01), degree of itch (ρ = 0.16, p < 0.01), disease severity (body surface area ρ = 0.16, p < 0.01 and psoriasis area severity index ρ=+0.15, p < 0.05). Both K10 and PHQ-9 showed significant correlations with PDI (ρ = 0.51 and ρ = 0.48, p < 0.01) and DLQI (ρ = 0.34 and ρ = 0.39, p = < 0.001). The presence of arthralgia was associated with psychological distress and depression (OR 1.8, 95% CI: 1.09, 3.05: p = 0.019, and OR 2.48, 95% CI: 1.32, 4.65: p = 0.004, respectively). There was no association between the psychological distress with gender, duration of the disease, or smoking status. Psychological distress is common in patients with CPP and it is associated with reduced QoL. Depression and suicidal ideation were notable concerns, and arthralgia was linked to higher levels of distress. These findings highlight the importance of addressing both physical and mental health in managing psoriasis. PMID:39820787 | DOI:10.1007/s00403-025-03808-9 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):254. doi: 10.1007/s00403-025-03809-8. NO ABSTRACT PMID:39821329 | DOI:10.1007/s00403-025-03809-8 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):268. doi: 10.1007/s00403-025-03805-y. ABSTRACT The relationship between psoriasis and osteopenia remains undetermined. Patients with psoriasis tend to have a higher Body Mass Index (BMI) compared to those without the condition. While it appears plausible that BMI could mediate this association, further study is required to confirm this hypothesis. The objective of this study is to ascertain whether BMI plays a role in influencing the impact of psoriasis on osteopenia. This study encompassed 2,624 participants from the National Health and Nutrition Examination Survey (NHANES) conducted between 2003 and 2006. The condition of psoriasis was self-reported, while osteopenia was assessed based on bone mineral density (BMD) range and self-reported osteoporosis. BMI was derived from NHANES body measurement data. Weighted logistic regression analyses and mediation analysis were utilized to elucidate the relationship. Subgroup differences were further explored in the absence of a clear relationship. A positive correlation was observed between psoriasis and osteopenia. Furthermore, BMI was positively related to psoriasis and negatively related to osteopenia. Additionally, BMI served as a mediator in the relationship between psoriasis and osteopenia, accounting for 20.8% of the variance. Specifically, the mediating influence of BMI exhibited variations based on diabetes status and gender. In conclusion, Controlling BMI could potentially mitigate the impact of psoriasis on osteopenia. Therefore, we advocate for a rigorous focus on bone health in individuals with psoriasis, particularly among males and non-diabetic populations. PMID:39821427 | DOI:10.1007/s00403-025-03805-y Den ganzen Artikel lesen

Int J Dermatol. 2025 Jan 16. doi: 10.1111/ijd.17658. Online ahead of print. NO ABSTRACT PMID:39821776 | DOI:10.1111/ijd.17658 Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2025 Jan 17. doi: 10.1007/s13555-024-01328-4. Online ahead of print. NO ABSTRACT PMID:39821856 | DOI:10.1007/s13555-024-01328-4 Den ganzen Artikel lesen

Cureus. 2024 Dec 16;16(12):e75810. doi: 10.7759/cureus.75810. eCollection 2024 Dec. ABSTRACT Introduction The COVID-19 pandemic sparked an interest in skincare with the closure of spas and salons. Skincare, one of TikTok's most popular dermatology-related hashtags, received hundreds of millions of views. The American Academy of Dermatology (AAD) shared facial cleansing recommendations; however, how many people follow them is unclear. Studies have shown a good daily facial cleansing and moisturizing routine can increase microbiome diversity and skin hydration. This can be beneficial in conditions like psoriasis, eczema, and acne. Purpose The aim of the study is to assess how well people follow the AAD recommendations and evaluate any differences in this behavior by gender. Methods A 19-question survey was designed and administered utilizing Qualtrics. The questions included demographic information, facial cleansing practices, and motivation for skincare routine. The survey was distributed via Rowan Email and on various social media platforms (GroupMe, Instagram, etc.) to target the general population. The data was analyzed using SPSS. Results One hundred twenty-four responses were collected from 91 female-identifying and 33 male-identifying participants. There were statistically significant differences between genders for the use of non-alcoholic gentle cleanser (p<0.001), use of moisturizer after washing the face (p<0.001), washing the face after sweating (p<0.001), and using warm water (p=0.026). No statistically significant difference was seen for face washing occurrence between genders (p=0.098). Statistically significant differences were seen between genders for motivation: hygiene (p<0.001), beauty/anti-aging (p<0.001), and health (p=0.004). Conclusion Individuals who identify as female may be more likely to adhere to AAD facial skincare recommendations. This could be a result of self-reported motivations such as hygiene, beauty, and health. PMID:39822430 | PMC:PMC11735236 | DOI:10.7759/cureus.75810 Den ganzen Artikel lesen

JAAD Case Rep. 2024 Sep 12;53:90-92. doi: 10.1016/j.jdcr.2024.08.027. eCollection 2024 Nov. NO ABSTRACT PMID:39823051 | PMC:PMC11736156 | DOI:10.1016/j.jdcr.2024.08.027 Den ganzen Artikel lesen